Previous close | 0.8300 |
Open | 0.7900 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 660.00 |
Expiry date | 2024-06-21 |
Day's range | 0.7900 - 0.8300 |
Contract range | N/A |
Volume | |
Open interest | N/A |
All three of these companies saw buyers step up post-earnings, reflecting the positivity of their results.
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
The results, from a small trial of a drug called CT-388, hint that Roche could be a serious player in the weight-loss market in coming years.